Politics latest: New Reform MP to join Commons as Westminster returns after election shock
Staff will be allowed to refuse to take part in assisted dying, under new changes being proposed.
NHS pharmacists will be among those given permission to opt out of being involved in delivering the procedure, if assisted dying becomes legal in the UK.
An amendment to the Terminally Ill Adults (End of Life) Bill is being put forward by the potential law's originator, Kim Leadbeater, this week.
In it, the amendment will make clear that "no person" can be forced to take part in the lethal medical procedure.
Changes will also be made to employment law so that nobody who refuses to participate can be dismissed or face disciplinary action as a result.
Watch: Why has the Assisted Dying Bill divided opinions?
What does the draft legislation currently say on participation?
At the moment, the bill already exempts doctors and other health professionals from having to take part.
But the new amendment will expand this definition to say that "no person is under any duty to participate in the provision of assistance".
That means NHS workers like pharmacists and other staff will also be covered.
A strengthening of the Employment Rights Act will also mean those who don't take part will need to give no reason for opting out.
Leadbeater has said she understands "not all people working in and around the health and care sector would want to participate in the provision of assisted dying".
She added: "I promised during the lengthy committee hearings into the bill that I would look at how we could extend the 'opt-out' provisions, and that is what I will be proposing this week.
"As a result, nobody will be at risk of any detriment to their careers if, for any reason at all, they chose not to take part."
What's changed in the bill since it was introduced last year?
A reminder: the bill is a proposal to change the law in England and Wales so that terminally ill adults with less than six months to live would have the right to apply for an assisted death, subject to approval by two doctors and an expert panel.
It has gone through lots of changes since it was first introduced to the House of Commons in November, where MPs voted in favour - moving it on beyond the bill's first stage.
A promise of a High Court safeguard has been scrapped and replace with expert panels.
Meanwhile, the implementation period (when the service must be up and running by following the bill becoming law) has been doubled to a maximum of four years.
How much demand is there for an assisted dying service?
Analysis released on Friday suggested as many as 800 assisted deaths could take place in the first year of it being in place in England and Wales.
The 149-page government impact assessment into the bill said that the total number of assisted deaths is estimated to range from 164 and 787 in the first year, to between 1,042 and 4,559 in year 10.
The same document also set out potential costs of the service and reduced end-of-life care costs.
It estimated that the cost of setting up expert panels and a Voluntary Assisted Dying Commissioner would be an average of between £10.9 million to £13.6 million per year.
But it said it had 'not been possible' to estimate the overall implementation costs at this stage of the process, which could include IT, recruitment and training and could begin to kick in within 12 months of the bill getting Royal Assent.
While noting that cutting end-of-life care costs 'is not stated as an objective of the policy', the assessment estimated that such costs could be reduced by as much as an estimated £10 million in the first year and almost £60 million after 10 years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
29 minutes ago
- Daily Mirror
Big Brother star issues fake weight loss job warning after she 'almost died' from counterfeit
Former Big Brother star Aisleyne Horgan-Wallace issued a warning to those looking to buy Ozempic online after she 'almost died' from taking a counterfeit jab Former Big Brother star Aisleyne Horgan-Wallace issued a warning to Good Morning Britain viewers today after she 'nearly died' after taking suspected fake Ozempic. The former Big Brother star, who starred on series seven of the reality show, purchased what she thought was Ozempic on the black market after gaining 28lbs (2 stone). A number of people have used the diabetes drug in a bid to lose weight. Although some people use Ozempic to aid weight loss, it is not licensed for this and should only be used by people with diabetes to aid their symptoms. Joining Adil Ray and Charlotte Hawkins on the ITV morning show, Aisleyne revealed how she experienced vomiting, sight loss and pain when she bought what she believes now was a fake jab online. The star said she was "mortified" and didn't go public until months later, as she "felt so stupid". Aisleyne, who reveals she was in a bad place at the time after losing people close to her, says she "wasn't really thinking". She added: "I just followed my friend, she was in a WhatsApp group, she bought the stuff, and I thought 'okay, I'll just go for it.' "It was a really foolish thing to do and I want people never to do that. Don't copy me, because I thought I was going to die." Looking down the camera, addressing anyone who was thinking to purchase the same way as her, the Big Brother star said: "Don't do it guys!" After taking one week's worth, Aisleyne said she was fine, but after the second jab, she was in and out of consciousness in bed for three days. The TV star recalled: "There were bags of vomit, sorry to be so graphic, but I was just in such a bad place. My vision was gone in one eye, it was petrifying. I was really really scared." The Big Brother star brought a 'counterfeit jab' with her to the studio, which came along with no medical paperwork or instructions. The star was too mortified to call and ambulance, and told the hosts she had accepted her fate. "How can I use NHS resources for something I brought upon myself?", she asked. "I just accepted my fate." Andy, a representative for the MRHA, warned that the people responsible for this are "criminals" and said Aisleyne shouldn't be so hard on herself. He said: "They are exploiting people. They're doing it to make money with complete disregard to people's welfare, their health. It could have been a lot worse for Aisleyne and we've seen that. "We rely very heavily on people like Aisleyne reporting to us," he said. "And we will take action against these criminals." "The message is so simple; there is only one safe way to obtain these medicines. These are powerful medicines that can only be legitimately obtained on prescription."
Daily Mirror
29 minutes ago
- Daily Mirror
Mum found dead in Travelodge after 'doctors irreversibly damaged her brain'
Roisin Harron, 41, who died by suicide when her mental health failed to recover (Image: Triangle News) A mother-of-one died by suicide in a Travelodge after she was discharged from a in-patient mental health care where electroconvulsive therapy 'irreversibly damaged her brain.' Roisin Harron tragically died after she was discharged from specialist mental health services despite still struggling with postpartum psychosis, an inquest has heard. The South London 41-year-old had been suffering from the illness following the birth of her son in 2017. Roisin, who also had a history of depression, started treatment at Bethlem Royal Hospital, Bromley, in 2018 following a week of hypermania which is characterised as periods of extreme, elated moods. READ MORE: Falkirk asylum hotel protest 'concerning' as council chief tackles misinformation READ MORE: People nearing retirement age could boost annual State Pension payments by up to £694 London and Maudsley NHS Foundation Trust (Image: Google Maps) Roisin underwent several rounds of electroconvulsive therapy (ECT) as part of her treatment. ECT send an electric current through a patient's brain and should only be used as a short-term treatment according to NHS guidelines. Repeated ECT treatments are only recommended if a patient has previously responded well to the process. However, an inquest heard that it was 'impossible to underestimate the impact psychiatric medication had in Roisin's life' and that Roisin felt 'her brain was in some was irreversibly damaged', following the treatment. Her father, Mr Harron, a retired social worker, told the court he thought the approach to his daughter's treatment was 'too blase' and it was 'impossible to underestimate the impact' it had in his daughters life. Roisin was found dead at the London Crystal Palace Travelodge on June 17, 2024, just over a year after being discharged from specialist services. A postmortem examination revealed that she had overdosed on a cocktail of drugs. Her parents, Margaret McMahon and Henry Harron told the South London Coroner's Court in Croydon: 'Roisin had been so unwell and such a risk to herself. But there had been much progress over the years. 'She tried to help herself and seemed to want to do her best at the things that mattered to her—being a good mother, being good at her job and working hard on her relationships with family and friends. 'Prior to her illness, Roisin had an incredibly good memory, but during her hospitalisation her memory became quite impaired.' Roisin was lately diagnosed with bipolar disorder. Bipolar disorder often sees sufferers struggle with extreme mood changes from manic highs to depressive lows. She was prescribed a range of medications to try and manage her symptoms, including antipsychotics and lithium. Lithium is a common drug used for bipolar sufferers and is prescribed for at least 6 months However the trial and error approach to medicating the mother led to her experiencing more stress and anxiety. In April 2023, Roisin was discharged from the specialist mental health services at South London and Maudsley NHS Foundation Trust and put back into the care of her GP at Paxton Green Group Practice, London. Her family told the inquest they were unsure of the move and did not think she was well enough to manage her difficult symptoms in the community. They said: 'It was clear that beneath the smiling and friendly face that Roisin presented to the world, there were very difficult struggles going on. There was still a deep and enduring depression and so many anxieties.' They added: 'She put on a brave face, but she clearly missed having regular contacts that she had built up a good relationship with.' Rosin had to use local pharmacies to access her medication, many of which had issues with supply and distribution - her family said this led to the spiral which resulted in her death. Dr Aneesa Peer, a consultant psychiatrist based at the South London and Maudsley trust said when Roisin was discharged she was in remission. 'When patients are dealing well and are stable for at least a year and they are on a good treatment regime they are considered for discharge,' she said. After this time, they can return back to the specialist services under a scheme that ensures they will be seen within four weeks, rather than being added to longer waiting lists. 'She didn't refer herself back after being discharged,' Dr Peer told the inquest. 'Roisin was very astute around her medication and would advocate for herself very clearly and concisely. This is not someone who is waiting on support. 'Patients come back to us all the time. The door is open. I am not sure how we could have intervened.' Dr Mihir Khan, who carried out the postmortem concluded she died of cardiac arrest. Assistant coroner Victoria Webb confirmed death by suicide, adding that Roisin had suffered with postpartum psychosis. Postpartum Psychosis affects roughly one in 1,000 women every year. It can cause feelings of helplessness, as well as a loss of interest in the baby , with symptoms usually starting within the first two weeks. Postpartum psychosis is a serious mental illness that should be treated as a medical emergency. It can get worse rapidly and the illness can risk the safety of the mother and baby, according to the NHS. The Mirror contacted South London and Maudsley NHS Foundation Trust for comment. If you, or someone close to you, is experiencing postpartum psychosis, talk to a midwife, GP, health visitor or dial 111 - if there is an immediate threat to life, call 999. You can also call the Samaritans on 116123. For support and advice, visit Action On Postpartum Psychosis' website –
ITV News
an hour ago
- ITV News
New treatment for advanced bladder cancer 'which doubles survival time'
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. 'It was horrific': UK hair transplant patients left disfigured and scarred Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
